What ‘Modicare’ May Mean (Or Not) For Pharma In India

Ambitious and complex to say the least, India’s “Modicare” – the proposed National Health Protection Scheme – could have significant implications on market expansion in the country. Scrip brings you an early take from pharma industry experts on what to expect (or not) and where the key challenges lie.

Medicine
MODICARE IS EXPECTED TO EXPAND OPPORTUNITIES FOR PHARMA

India’s proposed massive National Health Protection Scheme (NHPS), which hopes to cover 100 million “poor and vulnerable” families with health cover of up to INR500,000 ($7,805) each annually for secondary and tertiary care hospitalization, is expected to facilitate significant market expansion.

Pharma industry executives anticipate a sharp expansion of demand for medicines in India, though pricing-related disturbances could stunt gains for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia